United Therapeutics Corp (BSP:U2TH34)
R$ 127 (0%) Market Cap: 108.94 Bil Enterprise Value: 95.31 Bil PE Ratio: 17.79 PB Ratio: 3.31 GF Score: 94/100

United Therapeutics Corporation at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2026 / 08:50PM GMT
Release Date Price: R$127
Terence Flynn;Martine Rothblatt
Morgan Stanley - Analyst;United Therapeutics Corporation - Chairman of the Board, Chief Executive Officer

All right. Well, thanks so much for joining us, everybody. I'm Terence Flynn, Morgan Stanley's US biopharma analyst.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

I'm very pleased to be hosting United Therapeutics this afternoon. Joining us from the company, we have Martine Rothblatt, who is the company's Chairperson and CEO; and Pat Poisson, who is EVP, Strategic Development. Thank you both so much for taking time out of your day to join us. Really appreciate it, and looking forward to the conversation.

Maybe Martine, first, I'll just turn it over to you to maybe make some framing comments before I launch into my questions, but thanks so much.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot